Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Lymphoid 1Dermatologic 1Breast 1

Conditions

Sarcoma 2Small Cell Lung Carcinoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leiomyosarcoma 1Hodgkin Disease 1Hematologic Neoplasms 1Hemangiosarcoma 1Dermatofibrosarcoma 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Breast Neoplasms 1

Interventions

Doxorubicin 13Gemcitabine 10Cyclophosphamide 10pazopanib 8Filgrastim 8Radiotherapy 7Ifosfamide 7Cisplatin 7Irinotecan 6Docetaxel 6Radiation 5Granulocyte Colony-Stimulating Factor 5Etoposide 5Trabectedin 4Magnetic Resonance Spectroscopy 4Celecoxib 4Busulfan 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3sargramostim 3pembrolizumab 3X-Rays 3Sirolimus 3Radiotherapy, Intensity-Modulated 3Paclitaxel 3Neoadjuvant Therapy 3Leucovorin 3Dexrazoxane 3Cryosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Sarcoma × TTI-621 × Clear all
NCT04996004 2024-12-11

TTI-621-03

Pfizer

Phase 2 Terminated
76 enrolled 53 charts
Sarcoma

Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Dermatofibrosarcoma

NCT02890368 2023-04-05

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Pfizer

Phase 1 Terminated
56 enrolled
BreastDermatologicLymphoidSarcoma

Breast Neoplasms, Carcinoma, Squamous Cell, Melanoma, Mycosis Fungoides, Sarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡